Prescription medication · Long-Acting Beta-2 Agonist (LABA)
indacaterol
Also sold as Arcapta Neohaler.
Data updated 2026-05-15
- 3
- InteractionsFew interactions
- Rx
- Availability
Verify with FDA → · CMS NADAC pricing →
What it does
Information not available.
Common side effects
Common cold symptoms (nasopharyngitis), High blood pressure (hypertension)
Key warnings
No specific warnings noted. Always follow your prescriber's instructions.
Known Drug Interactions
7.7 Inhibitors of Cytochrome P450 3A4 and P-gp Efflux Transporter Drug interaction studies with indacaterol, a component of UTIBRON NEOHALER, were carried out using potent and specific inhibitors of CYP3A4 and P-gp (i.e., ketoconazole, erythromycin, verapamil, and ritonavir). The data suggest that systemic clearance of indacaterol is influenced by modulation of both P-gp and CYP3A4 activities and that the 2-fold area under the curve (AUC) increase caused by the strong dual inhibitor ketoconazole reflects the impact of maximal combined inhibition.
Mechanism: Ketoconazole stops the body from breaking down indacaterol. This leads to higher levels of the drug in your blood.
What to do: Your doctor may need to watch you more closely for side effects while you take both medications.
7.7 Inhibitors of Cytochrome P450 3A4 and P-gp Efflux Transporter Drug interaction studies with indacaterol, a component of UTIBRON NEOHALER, were carried out using potent and specific inhibitors of CYP3A4 and P-gp (i.e., ketoconazole, erythromycin, verapamil, and ritonavir).
Mechanism: Verapamil blocks the enzymes that clear indacaterol from your system. This can cause the drug to build up in your body.
What to do: Tell your doctor if you notice any new side effects, as they may need to monitor your treatment.
7.7 Inhibitors of Cytochrome P450 3A4 and P-gp Efflux Transporter Drug interaction studies with indacaterol, a component of UTIBRON NEOHALER, were carried out using potent and specific inhibitors of CYP3A4 and P-gp (i.e., ketoconazole, erythromycin, verapamil, and ritonavir).
Mechanism: Erythromycin slows down how fast your body removes indacaterol. This can result in more of the drug staying in your bloodstream.
What to do: Your healthcare provider should monitor you to make sure you do not experience too many side effects.
This is a plain-language summary of interactions documented in FDA labeling, not individualized advice. Ask a pharmacist or prescriber before combining medications.
Common Questions
What are the common side effects of indacaterol?
Does indacaterol interact with other medications?
What drug class is indacaterol?
Related Medications in Long-Acting Beta-2 Agonist (LABA)
Other drugs grouped near indacaterol - same-class peers and common alternatives.
aclidinium
Tudorza Pressair
Compare with indacaterol →
albuterol
Ventolin, ProAir
Albuterol is a drug that helps you breathe easier.
Compare with indacaterol →
albuterol/ipratropium
Combivent Respimat, DuoNeb
Combivent Respimat is a combination medicine that helps open your airways.
Compare with indacaterol →
beclomethasone
Qvar
Qvar Redihaler is an inhaled medicine that helps control asthma symptoms.
Compare with indacaterol →
benralizumab
Fasenra
Fasenra is a medicine that can help treat severe asthma and EGPA.
Compare with indacaterol →
Medication Guides
Understanding Drug Interactions
How CYP450 enzymes, inhibitors, and inducers affect your medications
Generic vs Brand Name Drugs
FDA requirements, cost savings, and when the difference matters
Narrow Therapeutic Index Drugs
Why some drugs demand precise dosing and monitoring
Common Drug Interactions
Dangerous medication combinations and how to protect yourself
Save on indacaterol
Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.
Disclosure: This link may earn us a commission at no extra cost to you. See our terms.
What the FDA Data Shows for indacaterol
The FDA label for indacaterol (sold under brand names such as Arcapta Neohaler) classifies it as a prescription-only medication in the Long-Acting Beta-2 Agonist (LABA) class. Regulatory labeling describes its approved uses and the patient populations studied in pre-market trials. Official labeling lists 2 commonly reported side effects, including Common cold symptoms (nasopharyngitis), High blood pressure (hypertension).
Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. Voluntary reports accumulate over the lifetime of a drug and reflect wide-ranging clinical use. The database also lists 3 documented drug interactions derived from FDA labeling, with the top-flagged interaction rated minor severity. Acquisition-cost data is surveyed weekly by CMS and updated as manufacturers report changes.
Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information further shape supply and switching decisions. This page summarizes public FDA data for educational purposes only and is not a substitute for professional medical advice, always consult a licensed healthcare provider before starting, stopping, or changing any medication.
Data Sources
Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS).
FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. Always consult a healthcare professional before making medication decisions.
Last updated: July 30, 2021
Read our methodology - how this data is sourced, computed, and verified.
Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled and last refreshed May 2026. See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
All federal data sources used on this page
- FDA Orange Book - approved drug products with therapeutic equivalence. accessdata.fda.gov/cder/ob
- FDA DailyMed - NIH-hosted drug labeling for FDA-approved meds. dailymed.nlm.nih.gov
- FDA Adverse Event Reporting System (FAERS) - post-marketing safety surveillance. fda.gov/drugs/faers
- NLM RxNorm - standardized clinical drug nomenclature. nlm.nih.gov/research/umls/rxnorm
- CMS Medicare Part B Drug Average Sales Price Files - federal drug pricing data. cms.gov/medicare/part-b-drugs/asp
- FDA Drug Shortages Database - current and resolved drug shortage tracking. accessdata.fda.gov/drugshortages